Hannah Joseph Hospital operates a 133-bed multi-specialty hospital in Chinthamani, Madurai, focused on Neurosciences, Cardiac Sciences, Orthopaedics and Traumatology. It earns revenue from in-patient and out-patient hospital services, including admissions, surgeries, diagnostics and consultations, with the facility ranked No. 1 in Madurai in Single Speciality Neuro Sciences and No. 2 in Multi Speciality Emergency and Trauma in the Times Health Survey 2026. Average revenue per occupied bed (ARPOB) rose from ₹80 lakh to ₹139 lakh, and FY26 revenue was ₹92.05 crore with an EBITDA margin of 27.92%. The company raised ₹4,200 lakhs through an IPO on the BSE SME platform in January 2026, with ₹3,498.21 lakhs earmarked for a Radiation Oncology Centre, of which only ₹70.80 lakhs had been deployed by March 2026. Promoters held 71.28% of equity, and management has also outlined plans for an Oncology Centre, Pharmacy and Laboratory Services on adjacent land already acquired. The single largest cost component is other operating expenses at 46.9% of revenue, followed by employee costs at 10.6% and depreciation at 7.3%. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Hospital services — Neurosciences, Hospital services — Cardiac Sciences, Hospital services — Orthopaedics and Traumatology, Planned Radiation Oncology services. Single-location, asset-heavy, specialty-focused hospital
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 92 |
| EBITDA (ex other income) | 25 |
| margin % | 27.4 |
| Owners' profit | 11 |
| EPS, as reported (₹) | 6.32 |
| ROE % · ROCE % | 11.5 · 15.5 |
| Debt / equity (x) | 0.27 |
| Cash from operations | 21 |
| Capex | (10) |
| ₹ crore | Q4 FY26 |
|---|---|
| Revenue | 50 |
| Profit before tax | 9 |
| Net profit | 6 |
| EPS (₹) | 3.43 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| APOLLO HOSPITALS ENTER. L | 1,27,062 | 60.8 | 12.74 | 33.5 | 20.1 | 16.6 | 19.0 | 16.2 |
| MAX HEALTHCARE INS LTD | 1,00,993 | 69.2 | 9.40 | 44.0 | 13.4 | 11.1 | 27.3 | 27.0 |
| FORTIS HEALTHCARE LTD | 67,025 | 64.0 | 6.59 | 32.9 | 10.5 | 9.7 | 17.8 | 22.0 |
| ASTER DM QUALITY CARE LTD | 39,689 | 124.0 | 8.21 | 40.4 | 8.8 | 8.5 | (11.6) | 14.3 |
| GLOBAL HEALTH LIMITED | 38,972 | 70.0 | 9.78 | 39.4 | 13.9 | 13.5 | — | 23.7 |
| NARAYANA HRUDAYALAYA LTD. | 38,213 | 46.5 | 8.42 | 25.4 | 17.8 | 9.2 | 25.0 | 18.8 |
| KRISHNA INST OF MED SCI L | 32,235 | 150.5 | 12.60 | 43.4 | 9.5 | 5.1 | 24.0 | 20.3 |
| DR AGARWALS HEALTH CARE L | 16,043 | 107.9 | 7.57 | 26.2 | 7.9 | 7.1 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 9 Sept 2026 · Hannah Joseph Hospital wins CII Best Healthcare Digital Initiative award | business updates | medium | — | — |
| 1 Sept 2026 · Hannah Joseph Hospital wins AHPI-TN Excellence Award 2026 | business updates | medium | — | — |
| 11 Aug 2026 · Promoter Daniel Dayanand Fenn buys 2,000 shares open market | ownership changes | medium | — | — |
| 16 Jul 2026 · AGM results: all 3 resolutions passed, Rs 2 dividend declared | compliance | minimal | — | — |
| 15 Jul 2026 · 15th AGM held; maiden dividend of Rs 2 per share declared | board shareholder meetings | low | — | — |
| 8 Jul 2026 · Ranked No. 1 in Madurai for Neuro Sciences in Times Health Survey 2026 | business updates | medium | — | — |
| 4 Jul 2026 · RTA compliance certificate submitted for quarter ended June 30, 2026 | compliance | minimal | — | — |
| 19 Jun 2026 · 15th AGM notice published in two newspapers | compliance | minimal | — | — |
| 18 Jun 2026 · Annual Report FY26 submitted; maiden dividend of Rs 2 per share | compliance | low | — | — |
| 16 Jun 2026 · Notice of 15th AGM on July 15, 2026 via video conferencing | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| — |
| 28.8 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 32.1 | 47.3 | 12 of 30 | 62% |
| P/B | 2.6 | 6.2 | 5 of 24 | 83% |
| ROCE | 13.1 | 10.9 | 11 of 30 | 66% |
| ROE | 11.5 | 11.8 | 13 of 24 | 48% |
| Debt / Equity | 0.3 | 0.2 | 14 of 24 | 44% |
| EBITDA margin | 27.8 | 22.0 | 7 of 24 | 74% |
| Market cap | 250 | 2415 | 22 of 30 | 28% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
